Empowering people, informing care decisions.
Empowering people, informing care decisions.
At Castle, it all comes down to people. After all, disease doesn’t just happen — it happens to people. We believe that disease management and treatment decisions can be better informed through a person’s unique biology, which is revealed through the scientific rigor of our innovative tests. We are committed to empowering healthcare providers and patients with the goal of improved outcomes.
Focus on the person behind every diagnosis. Apply precision genomics to bring sharper answers to the moments that matter—diagnosis, treatment, and follow‑up. Give care teams and patients the confidence to choose the right next step and avoid unnecessary procedures. Advance care that is personal, data‑driven, and designed to improve lives.
Clinical focus areas
Our broad portfolio of innovative tests focuses on answering critical clinical questions. Our tests are designed to deliver personalized information that better informs care decisions.
.svg)
Featured spotlights
A prospective DECIDE cohort analysis demonstrates that the DecisionDx-Melanoma i31-SLNB result more accurately stratifies patients by risk of SLN positivity than the MIA nomogram, supporting more accurate, risk-aligned SLNB decision-making and more personalized patient management.
A prospective multi-center trial to confirm use of the integrated 31-gene expression profile test (i31-SLNB) in patients with cutaneous melanoma to predict sentinel lymph node biopsy (SLNB) positivity and assess recurrence rates in those considered low risk by i31-SLNB who did not have an SLNB.
This article, part of the 2025 USA TODAY Skin Health Campaign, highlights how DecisionDx-Melanoma empowers patients and clinicians to co-create individualized care plans based on tumor biology. Featuring patient advocate Leah Adams, it emphasizes how 31-GEP testing provides both clinical clarity and peace of mind.
Despite definitive surgical treatment, a subset of cutaneous squamous cell carcinomas (cSCC) has an increased risk of regional or distant metastasis, making it challenging to identify patients most at risk. The 40-gene expression profile (40-GEP) prognostic test improves risk stratification for patients with cSCC who have known clinical or histologic risk factors, categorizing their risk of metastasis as low (Class 1), higher (Class 2A), or highest (Class 2B).
Brent Moody, MD, FACP, FAAD discusses how MyPath Melanoma raised red flags in a 26-year-old patient with multiple pigmented lesions.
Relentless pursuit of the best outcomes
At Castle, we combine innovation, advanced technologies and relevant real-world evidence to address critical unmet clinical needs and improve health outcomes.
The validity and utility of Castle’s innovative tests has been demonstrated in more than 150 peer-reviewed publications, and more than 300,000 test reports have been delivered to clinicians since 2008 to guide improved disease management decisions for patients.
The latest
Press Release
We are transforming disease management. Join in the transformation.
Every employee at Castle has an impact on patient care. If you are interested in making a difference in the lives of patients while doing something that inspires you, find out what exciting opportunities are available within our team.
%402x.b1d6d28a.webp)